

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6858576

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT	08/06/2021

RECEIVING PARTY DATA

Name:	ARBOR PHARMACEUTICALS, LLC
Street Address:	SIX CONCOURSE PARKWAY, SUITE 1800
City:	ATLANTA
State/Country:	GEORGIA
Postal Code:	30328

PROPERTY NUMBERS Total: 27

Property Type	Number
Patent Number:	7838023
Patent Number:	6087479
Patent Number:	6352709
Patent Number:	6471978
Patent Number:	6255277
Patent Number:	6465463
Patent Number:	6784177
Patent Number:	7235237
Patent Number:	6635273
Patent Number:	7708989
Patent Number:	7537785
Patent Number:	7556824
Patent Number:	7345037
Patent Number:	7160920
Patent Number:	7449595
Patent Number:	7772278
Patent Number:	7176238
Patent Number:	6656966
Patent Number:	6579863
Patent Number:	5958926

PATENT

Property Type	Number
Patent Number:	5380758
Patent Number:	5648393
Patent Number:	8067464
Application Number:	10594990
Application Number:	12564550
Application Number:	12096875
Application Number:	12300593

CORRESPONDENCE DATA

Fax Number: (404)873-8501

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4048738500

Email: trademarks@agg.com

Correspondent Name: ANUJ DESAI - ARNALL GOLDEN GREGORY LLP

Address Line 1: 171 17TH STREET NW

Address Line 2: SUITE 2100

Address Line 4: ATLANTA, GEORGIA 30363

ATTORNEY DOCKET NUMBER: 24209.20

NAME OF SUBMITTER: ANUJ DESAI

SIGNATURE: /Anuj Desai/

DATE SIGNED: 08/11/2021

Total Attachments: 5

source=Patent Release-GE, HFP#page1.tif

source=Patent Release-GE, HFP#page2.tif

source=Patent Release-GE, HFP#page3.tif

source=Patent Release-GE, HFP#page4.tif

source=Patent Release-GE, HFP#page5.tif

**NOTICE OF RELEASE OF
SECURITY INTEREST IN PATENTS**

August 6, 2021

WHEREAS, pursuant to that certain Patent Security Agreement (the "Patent Security Agreement"), dated as of February 22, 2013, by the Grantors (as defined therein), in favor of General Electric Capital Corporation ("GE"), as administrative agent for certain Secured Parties (as defined therein), and recorded in the United States Patent and Trademark Office on February 28, 2013 at Reel/Frame No. 29893/603, as such Patent Security Agreement was thereafter assigned to Healthcare Financial Solutions, LLC, as successor agent ("Healthcare Financial Solutions"), pursuant to that certain Assignment of Intellectual Property Security Agreement ("Assignment"), dated as of November 13, 2015, by and between GE and Healthcare Financial Solutions and recorded in the United States Patent and Trademark Office on November 15, 2015 at Reel/Frame No. 37112/69, each Grantor conveyed and granted to GE a security interest in and to the entire right, title and interest of each Grantor in and to the registered patents and pending applications shown in the attached Schedule A (collectively, the "Patents"), including, without limitation, all renewals thereof, all proceeds of infringement suits, the rights to sue for past, present and future infringements and all rights corresponding thereto and the goodwill of the business to which each of the Patents relates; and

WHEREAS, Healthcare Financial Solutions wishes to provide a document suitable for recording in the United States Patent and Trademark Office to evidence the release, relinquishment and discharge of its liens on and security interest in the Patents.

NOW, THEREFORE, in consideration of and in exchange for good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, Healthcare Financial Solutions, as administrative agent for the Secured Parties, hereby, without any representation and warranty and without any recourse to Healthcare Financial Solutions, terminates, cancels, reassigns, relinquishes, releases and discharges all liens and security interests it has in the Patents.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Notice of Release of Security Interest in Patents to be duly executed as of date first written above.

HEALTHCARE FINANCIAL SOLUTIONS, LLC,
as agent

By: 

Name: Alaina M. Powers

Title: Duly Authorized Signatory

SCHEDULE A - NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS

Patent Registrations

1. REGISTERED PATENTS

Nitromed, Inc. has rights in the following registered patents:

<u>Patent Description</u>	<u>Country</u>	<u>Patent Number</u>	<u>Registration Date</u>
Furoxan Compounds Compositions and Methods of Use	US	7,838,023	November 23, 2010
Localized Use of Nitric Oxide Adducts To Prevent Internal Tissue Damage	US	6,087,479	July 11, 2000
Localized Use of Nitric Oxide Adducts To Prevent Internal Tissue Damage	US	6,352,709	March 5, 2002
Localized Use of Nitric Oxide-Adducts To Prevent Internal Tissue Damage	US	6,471,978	October 29, 2002
Localized Use of Nitric Oxide-Adducts To Provent Internal Tissue Damage	US	6,255,277	July 3, 2001
Methods of Treating and Preventing Congestive Heart Failure With Hydralazine Compounds and IsosorbideDinitrate or Isosorbide	US	6,465,463	October 15, 2002
Methods of Treating and Preventing Congestive Heart Failure With Hydralazine Compounds and IsosorbideDinitrate or Isosorbide	US	6,784,177	August 31, 2004
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	AU	780261	June 23, 2005
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	CA	2,386,954	December 13, 2011
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	DE	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	EP	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	FR	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	GB	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	IT	1244455	July 22, 2009
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	US	7,235,237	June 26, 2007
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	US	6,635,273	October 21, 2003
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	US	7,708,989	May 4, 2010
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency- (Composition for Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency)	US	7,537,785	May 26, 2009
Methods of Treating Vascular Diseases Characterized	US	7,556,824	July 7, 2009

By Nitric Oxide Insufficiency- (Transdermal Patch Composition For Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency)			
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	AU	733202	August 23, 2001
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	CA	2,248,800	February 21, 2012
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	US	7,345,037	March 18, 2008
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	US	7,160,920	January 9, 2007
Nitrosated and Nitrosylated Prostaglandins Compositions and Methods of Use	US	7,449,595	November 11, 2008
Nitrosated and Nitrosylated Prostaglandins Compositions and Methods of Use	US	7772278	August 10, 2010
Nitrosated and Nitrosylated Prostaglandins Compositions and Methods of Use	US	7,176,238	February 13, 2007
Nitrosated and nitrosylatedtaxanes, compositions and methods of use	US	6,656,966	December 2, 2003
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders	US	6,579,863	June 17, 2003
Nitrosated and nitrosylatedphosphodiesterase inhibitor compounds, compositions and their uses	US	5,958,926	September 28, 1999
S-Nitrosothiols As Smooth Muscle Relaxants and Therapeutic Uses Thereof	US	5,380,758	October 10, 1995
Treatment of Male Impotence With S-Nitrosylated Compounds	US	5,648,393	July 15, 1997
Use of Nitric Oxide-Adducts To Prevent Thrombosis On Artificial and Vascular Surfaces	CA	2,170,772	March 29, 2005
Use of Nitric Oxide-Adducts To Prevent Thrombosis On Artificial and Vascular Surfaces	AU	698748	February 18, 1999
Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors	US	8,067,464	November 29, 2011

2. PATENT APPLICATIONS

Nitromed, Inc. has rights in the following patent applications:

<u>Patent Description</u>	<u>Country</u>	<u>Application Number</u>	<u>Filing Date</u>
Compositions for Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency	US	12/564,550	September 22, 2009
Methods For Treating Blood Disorders With Nitric Oxide Donor Compounds	CA	2,561,141	March 31, 2004
Methods For Treating Blood Disorders With Nitric Oxide Donor Compounds	EP	05767498.8	March 31, 2005
Methods For Treating Blood Disorders With Nitric Oxide Donor Compounds	US	10/594990	September 26, 2006

Methods For Treating Respiratory Disorders	AU	2006299383	October 4, 2006
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	AU	2007217980	February 12, 2007
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	CA	2,634,473	February 12, 2007
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	EP	7750648.3	February 12, 2007
Methods Using Hydralazine Compounds and IsosorbideDinitrate or IsosorbideMononitrate	US	12/096875	August 17, 2008
Methods of Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency	CA	2,678,256	May 2, 2001
Nitrosated and Nitrosylated Compounds and Compositions and Their Use For Treating Respiratory Disorders	EP	97916818.4	March 19, 1997
Solid Dosage Formulations of Hydralazine Compounds	CA	2,652,135	May 16, 2007
Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds	US	12/300593	May 6, 2009